ADVERTISEMENT

Afinitor Boosts Effectiveness of Hormonal Therapy

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

BY MELISSA WEBER
PUBLISHED THURSDAY, DECEMBER 9, 2010
Adding Afinitor (everolimus) to tamoxifen helped women with metastatic breast cancer live four months longer without their disease getting worse, according to a study presented Thursday at the San Antonio Breast Cancer Symposium.

Researchers randomly assigned 111 women to receive tamoxifen alone or tamoxifen plus Afinitor. Patients getting the combination lived a median of 8.6 months without disease progression, compared with 4.5 months for the tamoxifen-only group. After a median follow-up of around 22 months, nine patients in the combination arm had died compared with 25 deaths in the tamoxifen arm. All patients in this phase 2 trial had estrogen receptor–positive breast cancer that had previously been treated with an aromatase inhibitor, like Femara (letrozole) or Arimidex (anastrozole).

Afinitor—already approved for advanced kidney cancer—works by targeting mTOR, a protein that helps regulate the growth of cancer cells and blood vessels. Side effects associated with Afinitor include mouth ulcers, infections, cough and fatigue.

Three phase 3 studies, nicknamed BOLERO—short for Breast cancer trials of OraL EveROlimus— are now under way testing Afinitor in patients with locally advanced or metastatic breast cancer. one study will look at Afinitor in combination with the HER2-targeted drug Herceptin (trastuzumab) and the chemotherapy drug Taxol (paclitaxel). A second study will test the mTOR inhibitor in combination with Aromasin (exemestane), an aromatase inhibitor used to treat postmenopausal women with estrogen receptor–positive breast cancer. The third study will combine Afinitor with Herceptin and vinorelbine, a chemotherapy agent.

ADVERTISEMENT
Related Articles
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Overcoming the Mental Battle of  Metastatic Cancer
The mental challenges of having stage 4 breast cancer are just as overwhelming as the physical ones.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$